INZY has 36-month beta value of 1.46. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for INZY is 43.50M, and currently, short sellers hold a 7.42% ratio of that float. The average trading volume of INZY on November 22, 2024 was 263.62K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
INZY) stock’s latest price update
Inozyme Pharma Inc (NASDAQ: INZY)’s stock price has decreased by -3.58 compared to its previous closing price of 2.79. However, the company has seen a -21.57% decrease in its stock price over the last five trading sessions. zacks.com reported 2024-11-13 that Inozyme Pharma (INZY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
INZY’s Market Performance
Inozyme Pharma Inc (INZY) has experienced a -21.57% fall in stock performance for the past week, with a -45.10% drop in the past month, and a -50.19% drop in the past quarter. The volatility ratio for the week is 9.27%, and the volatility levels for the past 30 days are at 7.15% for INZY. The simple moving average for the last 20 days is -30.36% for INZY stock, with a simple moving average of -47.24% for the last 200 days.
Analysts’ Opinion of INZY
Many brokerage firms have already submitted their reports for INZY stocks, with Stifel repeating the rating for INZY by listing it as a “Buy.” The predicted price for INZY in the upcoming period, according to Stifel is $16 based on the research report published on September 12, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see INZY reach a price target of $17, previously predicting the price at $16. The rating they have provided for INZY stocks is “Buy” according to the report published on August 13th, 2024.
Wells Fargo gave a rating of “Overweight” to INZY, setting the target price at $14 in the report published on May 30th of the current year.
INZY Trading at -43.10% from the 50-Day Moving Average
After a stumble in the market that brought INZY to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -65.49% of loss for the given period.
Volatility was left at 7.15%, however, over the last 30 days, the volatility rate increased by 9.27%, as shares sank -45.21% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.14% lower at present.
During the last 5 trading sessions, INZY fell by -21.57%, which changed the moving average for the period of 200-days by -49.63% in comparison to the 20-day moving average, which settled at $3.86. In addition, Inozyme Pharma Inc saw -36.85% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at INZY starting from Treco Douglas A, who sale 7,523 shares at the price of $6.94 back on Apr 02 ’24. After this action, Treco Douglas A now owns 20,665 shares of Inozyme Pharma Inc, valued at $52,210 using the latest closing price.
Stock Fundamentals for INZY
Current profitability levels for the company are sitting at:
- -50.44 for the present operating margin
- 0.56 for the gross margin
The net margin for Inozyme Pharma Inc stands at -48.83. The total capital return value is set at -0.8. Equity return is now at value -79.42, with -55.29 for asset returns.
Based on Inozyme Pharma Inc (INZY), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -1.96. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -13.34.
Currently, EBITDA for the company is -74.81 million with net debt to EBITDA at -0.25. When we switch over and look at the enterprise to sales, we see a ratio of 98.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.68.
Conclusion
To put it simply, Inozyme Pharma Inc (INZY) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
